Shares of Dynavax Technologies Corp. jumped 34 percent after the company reported two-year data from a Phase II/III trial showing that its disease-modifying allergy drug, Tolamba, significantly reduced symptoms compared to placebo. (BioWorld Today)
Shares of Dynavax Technologies Corp. jumped 34 percent after the company reported two-year data from a Phase II/III trial showing that its disease-modifying allergy drug, Tolamba, significantly reduced symptoms compared to placebo. (BioWorld Today)
Cytokinetics Inc. is raising $33 million through a stock sale to fund clinical development of its lead products, including a heart failure drug that recently started a Phase I trial. (BioWorld Today)
Cytokinetics Inc. is raising $33 million through a stock sale to fund clinical development of its lead products, including a heart failure drug that recently started a Phase I trial. (BioWorld Today)
Expecting to triple the revenues from its research antibody division, MorphoSys AG is buying privately held Serotec Ltd. in a cash and stock deal valued at €29.3 million (US$35.3 million). (BioWorld International)
Expecting to triple the revenues from its research antibody division, MorphoSys AG is buying privately held Serotec Ltd. in a cash and stock deal valued at €29.3 million (US$35.3 million). (BioWorld International)
